| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 8 Jun 2026 | 3 Jun 2026 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/06/2026 inter alia to consider and approve Fund raising Issue of Shares and Warrants on Preferential basis pursuant to SEBI ICDR Regulations (As Per BSE Announcement Dated on:08.06.2026) | ||
| Board Meeting | 2 Jun 2026 | 27 May 2026 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve audited financial results of Quarter and Financial year ended on March 31 2026 Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2026 ,inter alia, to consider and approve audited financial results for quarter and year ended Marc 31, 2026 (As Per BSE Announcement Dated on:30.05.2026) Reschedule of Boar Meeting and Outcome of Board Meeting (As Per BSE Announcement Dated on:03.06.2026) | ||
| Board Meeting | 14 Feb 2026 | 10 Feb 2026 |
| Quarterly Results. Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Unaudited Financial results for quarter and nine months ended on December 31, 2025. Outcome of Board meeting for Financial Results (As Per BSE Announcement Dated on: 14/02/2026) | ||
| Board Meeting | 17 Nov 2025 | 8 Nov 2025 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve For approval of Unaudited Financial results for quarter ended September 30 2025. Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/11/2025 ,inter alia, to consider and approve Reschedule of Board Meeting supposed to be held on November 14, 2025 (As Per BSE Announcement Dated on: 15/11/2025) The Board Meeting was initially rescheduled on November 15, 2025 and thenafter on today i.e. November 17, 2025 hence Board has approved the Unaudited Financial statements for quarter and half year ended on September 30, 2025 The Board Meeting was initially rescheduled on November 15, 2025 and thenafter on today i.e. November 17, 2025 hence Board has approved the Unaudited Financial statements for quarter and half year ended on September 30, 2025. The Board meeting for approval of Financial statements was rescheduled initially on November 15, 2025 and thenafter on today i.e. November 17, 2025. The Board has approved the unaudited financial results for quarter and half year ended on September 30, 2025 . (As Per BSE Announcement Dated on: 17/11/2025) | ||
| Board Meeting | 14 Aug 2025 | 8 Aug 2025 |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve Board meeting to be held for Considering Unaudited Financial statements of the Company for Quarter ended June 30 2025 Approval of Financial results of Quarter ended 30th June 2025 (As Per BSE Announcement Dated on: 14.08.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
